Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Lung cancer marker and applications thereof

A marker and tumor marker technology, applied in the field of medical molecular biology, can solve the problems of lack of specificity and limited diagnostic value of lung cancer

Inactive Publication Date: 2017-04-19
ZHEJIANG UNIV
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although tumor markers related to lung cancer have been discovered continuously, these indicators lack specificity for the diagnosis of lung cancer and only have a certain reference value
On the other hand, due to the diversity of lung cancer histopathology, the heterogeneity of tumor cells with the same pathology, and the complexity and polymorphism of tumor biological behavior, the diagnostic value of single marker detection for lung cancer is limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lung cancer marker and applications thereof
  • Lung cancer marker and applications thereof
  • Lung cancer marker and applications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0012] Take 5ml of peripheral blood from each of the two groups, one group is the control group and the other is the test group, and the red blood is broken to prepare a single cell suspension, and the total amount of cells is adjusted to 5×10 6 For cells, add PE-TREM-2 to 10μl system, mix well and place in the dark, after 45min at room temperature, flow up, FCS / SSC gate analysis monocyte analysis TREM-2 + The proportion of cells and the expression abundance of TREM-2. On the 28th day, anesthetize the tumor-bearing mice to collect 1ml of blood from the eyeball, prepare a single cell suspension after breaking the redness, and adjust the total amount of cells to 5×10 6 Cells, add PE-CD14 and APC-TREM-2 in 10μl system, analyze TREM-2 by flow cytometry + CD14 + The proportion of cells and their expression abundance of TREM-2. The result is as figure 1 As shown, the peripheral blood mononuclear cells of the two groups were found, and the TREM-2 of the experimental group (patien...

Embodiment 2

[0014] Lung tissue samples obtained from lung cancer patients with different TNM stages were selected, including 15 cases of stage I, 15 cases of stage II, 15 cases of stage III, and 11 cases of stage IV. At the same time, lung tissue samples of 21 patients with other benign diseases were selected as the control group. By immunohistochemical staining (respectively labeled specific primary antibodies anti-TREM-2 and anti-F4 / 80), the results are as follows figure 2 showed that macrophages in the peritumoral tissue of lung cancer patients highly expressed TREM-2, and the expression of TREM-2 increased with tumor progression ( figure 2 A, B). At the same time, TREM-2 expression was positively correlated with lymph node metastasis ( figure 2 C). This shows that TREM-2 is closely related to the progression of lung cancer.

Embodiment 3

[0016] The changes of TREM-2 expression in peripheral blood mononuclear cells of patients with lung cancer were compared before and after surgery and before and after chemotherapy. The 20 enrolled patients were further divided into two groups according to the degree of tumor burden reduction. Group 1 included patients with stable lung cancer (SD) and patients with lung cancer progression (PD), and group 2 included patients with lung cancer partial remission (PR). The result is as image 3 , the expression of TREM-2 on the surface of monocytes was significantly reduced after effectively reducing the tumor burden. The expression level of TREM-2 on the surface of peripheral blood mononuclear cells in PR patients was significantly reduced after treatment, while TREM-2 in SD patients and PD patients did not change significantly, and even increased in some PD patients. This shows that TREM-2 may have a certain clinical value in evaluating the efficacy of chemotherapy in lung cancer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a lung cancer marker, which is a TREM-2 protein. The marker is a membrane surface acceptor, which is specifically expressed to myeloid derived dendritic cells and mononuclear macrophage, and belongs to the immunoglobulin superfamily. The expression of TREM-2 in peripheral blood mononuclear cells of lung cancer patients and tumor-bearing mice is obviously higher than the expression of TREM-2 in peripheral blood mononuclear cells of healthy persons and normal mice. The immunohistochemical method detection shows that high expression of TREM-2 exists in the macrophage of lung cancer patients and TREM-2 is in positive correlation with the development of lung cancer. The novel tumor marker (triggering receptors expressed on myeloid cells) namely TERM-2 can be used as a molecular marker of lung cancer diagnosis and treatment, has the advantages of convenience, rapidness, little damage, and easy reexamination, can be easily accepted by the patients, has an important meaning for the clinical diagnosis and treatment of lung cancer, and has a wide application prospect.

Description

technical field [0001] The invention belongs to the field of medical molecular biology and relates to a lung cancer marker TREM-2 and its application. Background technique [0002] Lung cancer is one of the most common malignant tumors, and its mortality rate ranks first in the world and in my country. The 2012 GLOBOCAN cancer report shows that the incidence and death of lung cancer accounted for 12.9% and 19.4% of the total number of cancer cases and deaths in that year, respectively. In 2013, there were 220,000 new lung cancer patients in the United States, and the proportion of cancer patients who died of lung cancer increased significantly (26% for men and 28% for women). In recent years, the prognosis of lung cancer patients has been improved by adopting comprehensive treatment measures combining surgery, chemotherapy, radiotherapy and targeted therapy. However, due to the lack of specific symptoms in the early stage of such patients, most of them have already reached...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/574G01N15/14
CPCG01N15/14G01N33/574G01N33/57423G01N33/57484
Inventor 周建英李和权姚一楠马文江陆国华
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com